AIM CONCEPT INTEGRATION
4th Year MBBS
Endocrine + Reproduction
4th Year MBBS
Endocrine + Reproduction
Diabetes Mellitus: Pathogenesis, Diagnosis, Chronic Management and Population Prevention
A rapid connection of disease mechanism, clinical recognition, pharmacological control and population prevention for KMU-focused revision. :contentReference[oaicite:0]{index=0}
1. THE TOPIC IN ONE CONNECTED FLOW
Diabetes develops when effective insulin action becomes inadequate. This may result from β-cell destruction, insulin resistance with progressive β-cell failure, or another defined cause. The same metabolic disturbance that produces hyperglycaemic symptoms also drives acute metabolic crises and, over time, retinal, renal, neural and macrovascular damage.
Cause / Predisposition
Autoimmune β-cell destruction or genetic susceptibility + visceral adiposity and inactivity
Autoimmune β-cell destruction or genetic susceptibility + visceral adiposity and inactivity
→
Core Mechanism
Absolute insulin deficiency or insulin resistance → compensatory hyperinsulinaemia → progressive β-cell dysfunction
Absolute insulin deficiency or insulin resistance → compensatory hyperinsulinaemia → progressive β-cell dysfunction
→
Metabolic Change
↓ Peripheral glucose uptake + inadequate suppression of hepatic glucose output → persistent hyperglycaemia
↓ Peripheral glucose uptake + inadequate suppression of hepatic glucose output → persistent hyperglycaemia
→
Clinical Presentation
Glycosuria → osmotic diuresis → polyuria and dehydration → polydipsia; severe insulin deficiency also promotes weight loss and ketosis
Glycosuria → osmotic diuresis → polyuria and dehydration → polydipsia; severe insulin deficiency also promotes weight loss and ketosis
→
Diagnosis
Fasting plasma glucose, HbA1c, 2-hour OGTT glucose or symptomatic random hyperglycaemia → classify type and assess complications
Fasting plasma glucose, HbA1c, 2-hour OGTT glucose or symptomatic random hyperglycaemia → classify type and assess complications
→
Intervention
Lifestyle modification + therapy targeted at insulin deficiency, insulin resistance, hepatic glucose production, incretin pathways or glucose absorption/excretion
Lifestyle modification + therapy targeted at insulin deficiency, insulin resistance, hepatic glucose production, incretin pathways or glucose absorption/excretion
→
Outcome / Complications
Poor control → DKA or HHS acutely; chronic hyperglycaemia → retinopathy, nephropathy, neuropathy and accelerated atherosclerosis
Poor control → DKA or HHS acutely; chronic hyperglycaemia → retinopathy, nephropathy, neuropathy and accelerated atherosclerosis
2. KEY CLINICAL CONNECTIONS
Insulin Deficiency versus Insulin Resistance
Rapid weight loss + ketosis
→
major insulin deficiency
→
type 1 diabetes pattern
→
major insulin deficiency
→
type 1 diabetes pattern
Central obesity + acanthosis nigricans
→
insulin resistance
→
compensatory hyperinsulinaemia and type 2 diabetes risk
→
insulin resistance
→
compensatory hyperinsulinaemia and type 2 diabetes risk
Acute versus Chronic Complications
Severe insulin deficiency
→
lipolysis + ketogenesis
→
DKA
→
lipolysis + ketogenesis
→
DKA
Persistent hyperglycaemia
→
glycation + oxidative/endothelial injury
→
microvascular and macrovascular disease
→
glycation + oxidative/endothelial injury
→
microvascular and macrovascular disease
Drug Mechanism Must Match the Defect
Metformin
→
↓ hepatic glucose production
→
glucose lowering with little hypoglycaemia when used alone
→
↓ hepatic glucose production
→
glucose lowering with little hypoglycaemia when used alone
Sulfonylurea / meglitinide
→
KATP channel closure
→
insulin release
→
hypoglycaemia risk
→
KATP channel closure
→
insulin release
→
hypoglycaemia risk
Population Risk to Prevention
Obesity + inactivity + genetic susceptibility
→
increasing type 2 diabetes burden
→
lifestyle-based primary prevention
→
increasing type 2 diabetes burden
→
lifestyle-based primary prevention
Asymptomatic high-risk person
→
biochemical screening
→
early diagnosis and secondary prevention
→
biochemical screening
→
early diagnosis and secondary prevention
3. AIM HIGH-YIELD INTEGRATION REVIEW
⭐ Type 1 diabetes: autoimmune β-cell destruction
→
absolute insulin deficiency
→
insulin replacement is essential.
→
absolute insulin deficiency
→
insulin replacement is essential.
⭐ Type 2 diabetes: insulin resistance
→
compensatory hyperinsulinaemia
→
progressive β-cell failure and hyperglycaemia.
→
compensatory hyperinsulinaemia
→
progressive β-cell failure and hyperglycaemia.
Hyperglycaemia
→
glycosuria and osmotic diuresis
→
polyuria, dehydration and polydipsia.
→
glycosuria and osmotic diuresis
→
polyuria, dehydration and polydipsia.
⭐ DKA versus HHS: profound insulin deficiency permits ketogenesis in DKA, whereas residual insulin in HHS limits major ketosis despite severe hyperglycaemia.
Chronic glucose excess
→
glycation and endothelial injury
→
retinopathy, nephropathy, neuropathy and accelerated atherosclerosis.
→
glycation and endothelial injury
→
retinopathy, nephropathy, neuropathy and accelerated atherosclerosis.
Insulin receptor tyrosine-kinase signalling
→
GLUT4 translocation in muscle and adipose tissue
→
increased glucose uptake.
→
GLUT4 translocation in muscle and adipose tissue
→
increased glucose uptake.
⭐ Drug-action link: secretagogues can cause hypoglycaemia; metformin and incretin-based therapies have less tendency to do so when used alone because they do not continuously force insulin release.
Population strategy: risk-factor reduction
→
primary prevention; screening and early treatment
→
secondary prevention; complication care and rehabilitation
→
tertiary prevention.
→
primary prevention; screening and early treatment
→
secondary prevention; complication care and rehabilitation
→
tertiary prevention.
AIM Exam Trap: Type 1 and type 2 diabetes should not be classified by age alone. A young patient can have type 2 diabetes, and autoimmune type 1 diabetes can present in adulthood; mechanism and clinical pattern are more reliable.